Dr. Van Huynh is a CHOC Children’s Specialist in oncology. She is board certified in both general pediatrics and pediatric hematology-oncology. Her clinical interests include childhood acute lymphoblastic leukemia (ALL), relapsed leukemia, immunotherapy, and bone marrow transplant.
Dr. Huynh attended medical school at UC Irvine College of Medicine, California. After completion of her pediatric residency training at Harbor-UCLA Medical Center, she served her fellowship in pediatric hematology-oncology at CHOC Children’s Hospital. She is CHOC’s principal investigator (PI) for Therapeutic Advances in Childhood Leukemia/Lymphoma (TACL) Consortium, which is a multi-center collaboration that offers novel treatment options for patients with relapsed or refractory leukemia and lymphoma. Dr. Huynh oversees the CAR T cell program and is the PI for the ZUMA-4 CAR T-cell Trial at CHOC Children’s.
Childhood acute lymphoblastic leukemia (ALL), relapsed leukemia, immunotherapy, bone marrow transplant
CHOC Children’s Hospital, Hyundai Cancer Institute
1201 W. La Veta Avenue
Orange, CA 92868
Sun W., JMalvar J., Sposto R., Anupam Verma A., Jennifer J. Wilkes J., Robyn DennisR., Kenneth Heym K., Theodore W. Laetsch T., Melissa Widener M., Susan R Rheingold S., Javier Oesterheld J., Nobuko Hijiya N., Maria Luisa Sulis M., Huynh V., Place A., Bittencourt H., Hutchinson R., Messinger Y., Chang B., Matloub Y., Ziegler D., Gardner,R. Cooper T., Ceppi F., Hermiston M., Dalla-Pozza L., Schultz K., Gaynon P., Wayne A., and Whitlock J. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a Therapeutic Advances in Childhood leukemia & lymphoma (TACL) study. Leukemia March 2018 doi:10.1038/s41375-018-0094-0
Huynh V, Laetsch T, Schore R, Gaynon P, O’Brien M. Redefining Treatment Failure for Pediatric Acute Leukemia in the Era of Minimal Residual Disease Testing. Pediatr Hematol Oncol. 2017 Nov 30:1-14 doi: 10.1080/08880018.2017.1397073
Huynh V. and Bergeron S. Asparaginase Toxicities – Identification and Management in Patients with Acute Lymphoblastic Leukemia. Clin Journ for Oncol Nurs CJON 2017, 21(5), E248-E259 DOI: 10.1188/17.CJON.E248-E259
Buchbinder D, Hsieh L, Puthenveetil G, Soni A, Stiles J, Huynh V, Kirov I, Neudorf S, Rubin E, Sender L, Torno L, Margolis D, Childs R, Moore T, Nugent D. Successful autologous cord blood transplantation in a child with acquired severe aplastic anemia. Pediatr Transplant. 2013 May;17(3):E104-7. PMID: 23464883. PMCID: PMC4174564. DOI: 10.1111/petr.12068.
Huynh V, Sender L, Bota DA. Acute lymphoblastic leukemia: What have we learned about the effects of this disease and its treatment on the nervous system? In: Faderl S (Ed.), Novel aspects in acute lymphoblastic leukemia (Chapter 4). 2011. ISBN 978-953-307-753-6. DOI: 10.5772/26833.
Lee D., Wayne S., Huynh V, Handgrettinger R., Brown P., Rossi J., Yizhou J, Jain R., et.al. KTE-C19 (Anti-CD19 chimeric Antigen Receptor T cell Therapy) in Pediatric and Adolescent Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R): Preliminary Results of ZUMA-4. Abstract for: The Society of Hematologic Oncology (SOHO) 5th Annual Meeting; September 2017; Houston, Texas
Shah B, Huynh V, Sender LS, Lee DW, Castro JE, Wierda WG, Dietz AC, Schiller GJ, Kersten MJ, Handgretinger R, Brown P, Gore L, Gökbuget N, Rosenthal J, Sabatino M, Bot A, Rossi JM, Jiang Y, Navale L, Stout S, Aycoc JS, Wiezorek J, Jain R, Wayne AS. High rates of minimal residual disease-negative (MRD-) complete responses (CR) in adult and pediatric patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) treated with KTE-C19 (anti-CD19 chimeric antigen receptor [CAR] T cells): Preliminary results of ZUMA-3 and ZUMA-4 trials. Oral presentation at: American Society of Hematology (ASH) 58th Annual Meeting & Exposition; December, 2016; San Diego, CA.
Love A and Huynh V., Outpatient management algorithm for febrile none-neutropenic or mildly neutropenic pediatric oncology patients with a central venous catheter. Abstract for 58th ASH Annual Meeting & Exposition; December, 2016; San Diego, CA
Burke, M., Brown P., Gore L., Bhojwani D., Chang B., Cooper T., DuBois S., Rebecca Gardner6, Gaynon P., Huynh V., Jeha S., Ziegler D., Wayne A., et.al. Pilot study of decitabine and vorinostat with chemotherapy for relapsed ALL: A report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) consortium. Abstract for: 58th ASH Annual Meeting & Exposition; December, 2016; San Diego, CA.
Foord A, Huynh V, Torno L. Carnitine: An innovative approach to treat fatty liver disease in pediatric ALL. Abstract for: The American Society of Pediatric Hematology/Oncology (ASPHO); May, 2016; Minneapolis, MN.
Gotesman M, Huynh V, Neudorf S. Changing the use of ferritin as a marker for iron overload in the pediatric post-transplant period. Abstract for: BMT Tandem Meetings (combined annual meetings of the Center for International Blood & Marrow Transplant Research [CIBMTR] and the American Society of Blood and Marrow Transplantation [ASBMT]; February, 2016; Honolulu, HI.
John T, Neudorf S, Kirov I, Ashouri N, Huynh V. Drug resistant CMV in pediatric hematopoietic stem cell transplant recipients. Abstract for: BMT Tandem Meetings; February, 2015; San Diego, CA.
Burke MJ, Brown P, Gore L, Sposto R, Bhojwani D, Chang BH, Dubois SG, Gaynon PS, Glade-Bender J, Heym KM, Sulis ML, Pollard JA, Verma A, Huynh V. Invasive Candida infections in pediatric patients treated on the pilot study of decitabine and vorinostat with chemotherapy for relapsed ALL: A report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) consortium. Abstract for: 56th American Society of Hematology (ASH) Annual Meeting; December, 2014; San Francisco, CA.
Huynh V, Kirov I, Neudorf S, Zadeh T, Lones M. Post-transplant lymphoproliferative disorders in pediatric bone marrow transplant recipients have non-germinal center-B phenotype and unique cytogenetic abnormalities. Abstract for: Fourth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin’s Lymphoma; November, 2012; New York, NY.
Neudorf S, Sender L, Torno L, Rubin E, Huynh V, Buchbinder D, Nourani A, Daum C, Klinger E, Dao D, Kirov I. Donor lymphocyte infusions (DLI) for treatment of relapsed leukemia following allogeneic stem cell transplantation in children. Abstract for 3rd International Conference on Immunotherapy in Pediatric Oncology; October, 2012; Frankfurt, Germany.
Juth V, Huynh V, Silver R, Sender L. Different sides of the same coin: A shared illness experience among adolescent and young adult cancer patients and their caregivers. Abstract for: Teenage Cancer Trust 7th International Conference on Teenage and Young Adult Cancer Medicine; June, 2012; London, United Kingdom.
Huynh V, Templeman T, Shen V. Toxicity profile of bevacizumab based regimens in the treatment of pediatric malignant brain tumors – A single institution’s experience. Abstract for: 14th International Symposium on Pediatric Neuro-Oncology; June, 2010; Vienna, Austria.
Huynh V, Anton-Culver H, Ziogas A. Risk factors for Wilms tumor. Abstract for: ASPHO 23rd Annual Meeting; April, 2010; Quebec, Canada.
Huynh V, Anton-Culver, Ziogas A. The epidemiology and clinical characteristics of Wilms tumor in California. Abstract for: American Association for Cancer Research (AACR) 100th Annual Meeting; April, 2009; Denver, CO.
Dr. Van Huynh is a CHOC Children’s Specialist in oncology. She is board certified in both general pediatrics and pediatric hematology-oncology.